{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:46:28Z","timestamp":1793339188140,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK134361"],"award-info":[{"award-number":["DK134361"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK126908"],"award-info":[{"award-number":["DK126908"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK090313"],"award-info":[{"award-number":["DK090313"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL133162"],"award-info":[{"award-number":["HL133162"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","award":["XU19XX0"],"award-info":[{"award-number":["XU19XX0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biosci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Sodium-Glucose cotransporter 1 and 2 (SGLT1\/2) belong to the family of glucose transporters, encoded by\n                      <jats:italic>SLC5A1<\/jats:italic>\n                      and\n                      <jats:italic>SLC5A2<\/jats:italic>\n                      , respectively. SGLT2 is almost exclusively expressed in the renal proximal convoluted tubule cells. SGLT1 is expressed in the kidneys but also in other organs throughout the body. Many SGLT inhibitor drugs have been developed based on the mechanism of blocking glucose (re)absorption mediated by SGLT1\/2, and several have gained major regulatory agencies\u2019 approval for treating diabetes. Intriguingly these drugs are also effective in treating diseases beyond diabetes, for example heart failure and chronic kidney disease. We recently discovered that SGLT1 is upregulated in the airway epithelial cells derived from patients of cystic fibrosis (CF), a devastating genetic disease affecting greater than 70,000 worldwide.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the present work, we show that the SGLT1 upregulation is coupled with elevated endoplasmic reticulum (ER) stress response, indicated by activation of the primary ER stress senor inositol-requiring protein 1\u03b1 (IRE1\u03b1) and the ER stress-induced transcription factor X-box binding protein 1 (XBP1), in CF epithelial cells, and in epithelial cells of other stress conditions. Through biochemistry experiments, we demonstrated that the spliced form of XBP1 (XBP1s) acts as a transcription factor for\n                      <jats:italic>SLC5A1<\/jats:italic>\n                      by directly binding to its promoter region. Targeting this ER stress \u2192\n                      <jats:italic>SLC5A1<\/jats:italic>\n                      axis by either the ER stress inhibitor Rapamycin or the SGLT1 inhibitor Sotagliflozin was effective in attenuating the ER stress response and reducing the SGLT1 level in these cellular model systems.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present work establishes a causal relationship between ER stress and SGLT1 upregulation and provides a mechanistic explanation why SGLT inhibitor drugs benefit diseases beyond diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13578-024-01203-x","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T13:02:48Z","timestamp":1708606968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["XBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions"],"prefix":"10.1186","volume":"14","author":[{"given":"Yifei","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Eugene","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9452-2878","authenticated-orcid":false,"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"1203_CR1","doi-asserted-by":"crossref","unstructured":"Deeks E D. Sotagliflozin: a review in type 1 diabetes. Drugs. 2019;79:1977\u201387.","DOI":"10.1007\/s40265-019-01230-w"},{"key":"1203_CR2","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.dsx.2019.04.041","volume":"13","author":"MF Hassanabad","year":"2019","unstructured":"Hassanabad MF, Abad ZFH. Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2? Diabetes Metab Syndr. 2019;13:1893\u20136.","journal-title":"Diabetes Metab Syndr"},{"key":"1203_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.13854","volume":"22","author":"RJ Chilton","year":"2020","unstructured":"Chilton RJ. Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes. Diabetes Obes Metab. 2020;22:16\u201329.","journal-title":"Diabetes Obes Metab"},{"key":"1203_CR4","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.7326\/M21-0651","volume":"174","author":"M Szarek","year":"2021","unstructured":"Szarek M, et al. Effect of Sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: a Randomized Trial. Ann Intern Med. 2021;174:1065\u201372.","journal-title":"Ann Intern Med"},{"key":"1203_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129\u201339.","journal-title":"N Engl J Med"},{"key":"1203_CR6","doi-asserted-by":"crossref","unstructured":"Jojima T et al. The SGLT2 inhibitor Canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related Hepatocarcinogenesis: Association with SGLT2 expression in Hepatocellular Carcinoma. Int J Mol Sci 20, (2019).","DOI":"10.3390\/ijms20205237"},{"key":"1203_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.eprac.2021.09.013","volume":"28","author":"CH Ng","year":"2022","unstructured":"Ng CH, et al. Antidiabetic medications for type 2 diabetics with nonalcoholic fatty liver disease: evidence from a Network Meta-Analysis of Randomized controlled trials. Endocr Pract. 2022;28:223\u201330.","journal-title":"Endocr Pract"},{"key":"1203_CR8","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.7150\/thno.54498","volume":"11","author":"Z Liu","year":"2021","unstructured":"Liu Z, et al. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics. 2021;11:4502\u201315.","journal-title":"Theranostics"},{"key":"1203_CR9","doi-asserted-by":"publisher","first-page":"747620","DOI":"10.3389\/fcvm.2021.747620","volume":"8","author":"JV Mui","year":"2021","unstructured":"Mui JV, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) inhibitors for New-Onset Dementia: a propensity score-matched Population-based study with competing risk analysis. Front Cardiovasc Med. 2021;8:747620.","journal-title":"Front Cardiovasc Med"},{"key":"1203_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.omtm.2021.11.008","volume":"24","author":"H Hirai","year":"2022","unstructured":"Hirai H, et al. The sodium\/glucose cotransporters as potential therapeutic targets for CF lung diseases revealed by human lung organoid swelling assay. Mol Ther Methods Clin Dev. 2022;24:11\u20139.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1203_CR11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.2475911","volume":"245","author":"JR Riordan","year":"1989","unstructured":"Riordan JR, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066\u201373.","journal-title":"Science"},{"key":"1203_CR12","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1056\/NEJMra043184","volume":"352","author":"SM Rowe","year":"2005","unstructured":"Rowe SM, Miller S. Sorscher, cystic fibrosis. N Engl J Med. 2005;352:1992\u20132001.","journal-title":"N Engl J Med"},{"key":"1203_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrm3270","volume":"13","author":"C Hetz","year":"2012","unstructured":"Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13:89\u2013102.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1203_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","volume":"185","author":"K Fiedorczuk","year":"2022","unstructured":"Fiedorczuk K, Chen J. Mechanism of CFTR correction by type I folding correctors. Cell. 2022;185:158\u2013168e111.","journal-title":"Cell"},{"key":"1203_CR15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1165\/rcmb.2008-0065OC","volume":"39","author":"R Bartoszewski","year":"2008","unstructured":"Bartoszewski R, et al. Activation of the unfolded protein response by deltaF508 CFTR. Am J Respir Cell Mol Biol. 2008;39:448\u201357.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1203_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-pathol-012513-104649","volume":"10","author":"SA Oakes","year":"2015","unstructured":"Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. Annu Rev Pathol. 2015;10:173\u201394.","journal-title":"Annu Rev Pathol"},{"key":"1203_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41574-021-00510-4","volume":"17","author":"J Yong","year":"2021","unstructured":"Yong J, Johnson JD, Arvan P, Han J, Kaufman RJ. Therapeutic opportunities for pancreatic beta-cell ER stress in diabetes mellitus. Nat Rev Endocrinol. 2021;17:455\u201367.","journal-title":"Nat Rev Endocrinol"},{"key":"1203_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41569-021-00511-w","volume":"18","author":"J Ren","year":"2021","unstructured":"Ren J, Bi Y, Sowers JR, Hetz C, Zhang Y. Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases. Nat Rev Cardiol. 2021;18:499\u2013521.","journal-title":"Nat Rev Cardiol"},{"key":"1203_CR19","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1007\/s12035-020-01929-y","volume":"57","author":"MS Uddin","year":"2020","unstructured":"Uddin MS, et al. Molecular mechanisms of ER stress and UPR in the pathogenesis of Alzheimer\u2019s Disease. Mol Neurobiol. 2020;57:2902\u201319.","journal-title":"Mol Neurobiol"},{"key":"1203_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/hep.32562","volume":"77","author":"A Ajoolabady","year":"2023","unstructured":"Ajoolabady A, et al. Endoplasmic reticulum stress in liver diseases. Hepatology. 2023;77:619\u201339.","journal-title":"Hepatology"},{"key":"1203_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen X, Cubillos-Ruiz JR. Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer. 2021;21:71\u201388.","journal-title":"Nat Rev Cancer"},{"key":"1203_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.tcb.2013.06.005","volume":"23","author":"Y Chen","year":"2013","unstructured":"Chen Y, Brandizzi F. IRE1: ER stress sensor and cell fate executor. Trends Cell Biol. 2013;23:547\u201355.","journal-title":"Trends Cell Biol"},{"key":"1203_CR23","doi-asserted-by":"crossref","unstructured":"Read A, Schroder M. The unfolded protein response: an overview. Biology (Basel) 10, (2021).","DOI":"10.3390\/biology10050384"},{"key":"1203_CR24","doi-asserted-by":"crossref","unstructured":"Park SM, Kang TI, So JS. Roles of XBP1s in Transcriptional Regulation of Target Genes. Biomedicines 9, (2021).","DOI":"10.3390\/biomedicines9070791"},{"key":"1203_CR25","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.bbrc.2005.04.039","volume":"331","author":"S Kanemoto","year":"2005","unstructured":"Kanemoto S, et al. XBP1 activates the transcription of its target genes via an ACGT core sequence under ER stress. Biochem Biophys Res Commun. 2005;331:1146\u201353.","journal-title":"Biochem Biophys Res Commun"},{"key":"1203_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.molcel.2007.06.011","volume":"27","author":"D Acosta-Alvear","year":"2007","unstructured":"Acosta-Alvear D, et al. XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks. Mol Cell. 2007;27:53\u201366.","journal-title":"Mol Cell"},{"key":"1203_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.celrep.2018.09.013","volume":"25","author":"EE Fink","year":"2018","unstructured":"Fink EE, et al. XBP1-KLF9 Axis acts as a Molecular Rheostat to control the transition from adaptive to cytotoxic unfolded protein response. Cell Rep. 2018;25:212\u2013223e214.","journal-title":"Cell Rep"},{"key":"1203_CR28","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/emboj.2011.52","volume":"30","author":"K Zhang","year":"2011","unstructured":"Zhang K, et al. The unfolded protein response transducer IRE1alpha prevents ER stress-induced hepatic steatosis. EMBO J. 2011;30:1357\u201375.","journal-title":"EMBO J"},{"key":"1203_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41580-020-0250-z","volume":"21","author":"C Hetz","year":"2020","unstructured":"Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol. 2020;21:421\u201338.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1203_CR30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1172\/JCI200521848","volume":"115","author":"K Zhang","year":"2005","unstructured":"Zhang K, et al. The unfolded protein response sensor IRE1alpha is required at 2 distinct steps in B cell lymphopoiesis. J Clin Invest. 2005;115:268\u201381.","journal-title":"J Clin Invest"},{"key":"1203_CR31","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1101\/gad.839400","volume":"14","author":"W Tirasophon","year":"2000","unstructured":"Tirasophon W, Lee K, Callaghan B, Welihinda A, Kaufman RJ. The endoribonuclease activity of mammalian IRE1 autoregulates its mRNA and is required for the unfolded protein response. Genes Dev. 2000;14:2725\u201336.","journal-title":"Genes Dev"},{"key":"1203_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2337\/db16-0052","volume":"66","author":"JM Wang","year":"2017","unstructured":"Wang JM, Qiu Y, Yang ZQ, Li L, Zhang K. Inositol-requiring enzyme 1 facilitates Diabetic Wound Healing through modulating MicroRNAs. Diabetes. 2017;66:177\u201392.","journal-title":"Diabetes"},{"key":"1203_CR33","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1210\/en.2010-1036","volume":"152","author":"J Ning","year":"2011","unstructured":"Ning J, et al. Constitutive role for IRE1alpha-XBP1 signaling pathway in the insulin-mediated hepatic lipogenic program. Endocrinology. 2011;152:2247\u201355.","journal-title":"Endocrinology"},{"key":"1203_CR34","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1080\/15548627.2015.1091141","volume":"11","author":"HO Rashid","year":"2015","unstructured":"Rashid HO, Yadav RK, Kim HR. Chae, ER stress: Autophagy induction, inhibition and selection. Autophagy. 2015;11:1956\u201377.","journal-title":"Autophagy"},{"key":"1203_CR35","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.transproceed.2015.05.013","volume":"47","author":"J Zhu","year":"2015","unstructured":"Zhu J, Hua X, Li D, Zhang J, Xia Q. Rapamycin attenuates Mouse Liver Ischemia and Reperfusion Injury by inhibiting endoplasmic reticulum stress. Transpl Proc. 2015;47:1646\u201352.","journal-title":"Transpl Proc"},{"key":"1203_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1210\/en.2014-1454","volume":"156","author":"H Wang","year":"2015","unstructured":"Wang H, et al. Restoration of autophagy alleviates hepatic ER stress and impaired insulin signalling transduction in high fructose-fed male mice. Endocrinology. 2015;156:169\u201381.","journal-title":"Endocrinology"},{"key":"1203_CR37","doi-asserted-by":"crossref","unstructured":"Yin J et al. Rapamycin improves palmitate-induced ER stress\/NF kappa B pathways associated with stimulating autophagy in adipocytes. Mediators Inflamm 2015, 272313 (2015).","DOI":"10.1155\/2015\/272313"},{"key":"1203_CR38","doi-asserted-by":"publisher","first-page":"626","DOI":"10.4161\/auto.23642","volume":"9","author":"E Bachar-Wikstrom","year":"2013","unstructured":"Bachar-Wikstrom E, Wikstrom JD, Kaiser N, Cerasi E, Leibowitz G. Improvement of ER stress-induced diabetes by stimulating autophagy. Autophagy. 2013;9:626\u20138.","journal-title":"Autophagy"},{"key":"1203_CR39","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/cdd.2011.98","volume":"19","author":"H Kato","year":"2012","unstructured":"Kato H, et al. mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway. Cell Death Differ. 2012;19:310\u201320.","journal-title":"Cell Death Differ"},{"key":"1203_CR40","doi-asserted-by":"publisher","first-page":"F267","DOI":"10.1152\/ajprenal.00629.2014","volume":"308","author":"G Dong","year":"2015","unstructured":"Dong G, et al. mTOR contributes to ER stress and associated apoptosis in renal tubular cells. Am J Physiol Ren Physiol. 2015;308:F267\u2013274.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1203_CR41","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.bbrc.2012.01.038","volume":"418","author":"SL Hwang","year":"2012","unstructured":"Hwang SL, Li X, Lee JY, Chang HW. Improved insulin sensitivity by rapamycin is associated with reduction of mTOR and S6K1 activities in L6 myotubes. Biochem Biophys Res Commun. 2012;418:402\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1203_CR42","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","volume":"377","author":"SK Garg","year":"2017","unstructured":"Garg SK, et al. Effects of Sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377:2337\u201348.","journal-title":"N Engl J Med"},{"key":"1203_CR43","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","volume":"61","author":"RJ McCrimmon","year":"2018","unstructured":"McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia. 2018;61:2126\u201333.","journal-title":"Diabetologia"},{"key":"1203_CR44","doi-asserted-by":"publisher","first-page":"154937","DOI":"10.1016\/j.metabol.2021.154937","volume":"127","author":"I Caruso","year":"2022","unstructured":"Caruso I, Giorgino F. SGLT-2 inhibitors as cardio-renal protective agents. Metabolism. 2022;127:154937.","journal-title":"Metabolism"},{"key":"1203_CR45","doi-asserted-by":"publisher","first-page":"e0156009","DOI":"10.1371\/journal.pone.0156009","volume":"11","author":"HM Rigden","year":"2016","unstructured":"Rigden HM, et al. Squamous metaplasia is increased in the bronchial epithelium of smokers with chronic obstructive Pulmonary Disease. PLoS ONE. 2016;11:e0156009.","journal-title":"PLoS ONE"},{"key":"1203_CR46","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1172\/JCI32526","volume":"117","author":"J Araya","year":"2007","unstructured":"Araya J, et al. Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J Clin Invest. 2007;117:3551\u201362.","journal-title":"J Clin Invest"},{"key":"1203_CR47","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1165\/rcmb.2022-0299OC","volume":"68","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, et al. Human airway basal cells undergo reversible squamous differentiation and reshape innate immunity. Am J Respir Cell Mol Biol. 2023;68:664\u201378.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1203_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.toxlet.2012.02.017","volume":"211","author":"JS Lee","year":"2012","unstructured":"Lee JS, et al. Pharmacologic ER stress induces non-alcoholic steatohepatitis in an animal model. Toxicol Lett. 2012;211:29\u201338.","journal-title":"Toxicol Lett"},{"key":"1203_CR49","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/B978-0-12-385116-1.00019-4","volume":"489","author":"Z Zheng","year":"2011","unstructured":"Zheng Z, Zhang C, Zhang K. Measurement of ER stress response and inflammation in the mouse model of nonalcoholic fatty liver disease. Methods Enzymol. 2011;489:329\u201348.","journal-title":"Methods Enzymol"},{"key":"1203_CR50","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.lfs.2018.04.022","volume":"203","author":"X Chen","year":"2018","unstructured":"Chen X, et al. Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis. Life Sci. 2018;203:291\u2013304.","journal-title":"Life Sci"},{"key":"1203_CR51","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/hep.24783","volume":"55","author":"C Zhang","year":"2012","unstructured":"Zhang C, et al. Endoplasmic reticulum-tethered transcription factor cAMP responsive element-binding protein, hepatocyte specific, regulates hepatic lipogenesis, fatty acid oxidation, and lipolysis upon metabolic stress in mice. Hepatology. 2012;55:1070\u201382.","journal-title":"Hepatology"},{"key":"1203_CR52","doi-asserted-by":"publisher","first-page":"102258","DOI":"10.1016\/j.coph.2022.102258","volume":"65","author":"CMP Ribeiro","year":"2022","unstructured":"Ribeiro CMP, Hull-Ryde EA. Functional role of the ER stress transducer IRE1alpha in CF airway epithelial inflammation. Curr Opin Pharmacol. 2022;65:102258.","journal-title":"Curr Opin Pharmacol"},{"key":"1203_CR53","first-page":"293","volume":"215","author":"AC Tang","year":"2017","unstructured":"Tang AC, et al. Endoplasmic reticulum stress and chemokine production in cystic fibrosis Airway cells: regulation by STAT3 modulation. J Infect Dis. 2017;215:293\u2013302.","journal-title":"J Infect Dis"},{"key":"1203_CR54","doi-asserted-by":"publisher","first-page":"pgac306","DOI":"10.1093\/pnasnexus\/pgac306","volume":"2","author":"Q Wu","year":"2023","unstructured":"Wu Q, et al. Cystic fibrosis rabbits develop spontaneous hepatobiliary lesions and CF-associated liver disease (CFLD)-like phenotypes. PNAS Nexus. 2023;2:pgac306.","journal-title":"PNAS Nexus"},{"key":"1203_CR55","doi-asserted-by":"publisher","first-page":"106","DOI":"10.31083\/j.rcm2303106","volume":"23","author":"R Nevola","year":"2022","unstructured":"Nevola R, et al. Cardiorenal Impact of SGLT-2 inhibitors: a conceptual revolution in the management of type 2 diabetes, heart failure and chronic kidney disease. Rev Cardiovasc Med. 2022;23:106.","journal-title":"Rev Cardiovasc Med"},{"key":"1203_CR56","doi-asserted-by":"crossref","unstructured":"Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health 16, (2019).","DOI":"10.3390\/ijerph16162965"},{"key":"1203_CR57","doi-asserted-by":"crossref","unstructured":"Pistelli L et al. Gliflozins: from antidiabetic drugs to cornerstone in heart failure Therapy-A Boost to their utilization and Multidisciplinary Approach in the management of heart failure. J Clin Med 12, (2023).","DOI":"10.3390\/jcm12010379"},{"key":"1203_CR58","doi-asserted-by":"crossref","unstructured":"Nasiri-Ansari N et al. Empagliflozin attenuates non-alcoholic fatty liver Disease (NAFLD) in High Fat Diet Fed ApoE((-\/-)) mice by activating Autophagy and reducing ER stress and apoptosis. Int J Mol Sci 22, (2021).","DOI":"10.3390\/ijms22020818"},{"key":"1203_CR59","doi-asserted-by":"crossref","unstructured":"Ala M. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD. Endocrinology 162, (2021).","DOI":"10.1210\/endocr\/bqab157"},{"key":"1203_CR60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3233\/JAD-215337","volume":"86","author":"J Secnik","year":"2022","unstructured":"Secnik J, et al. Glucose-lowering medications and Post-dementia Survival in patients with diabetes and dementia. J Alzheimers Dis. 2022;86:245\u201357.","journal-title":"J Alzheimers Dis"},{"key":"1203_CR61","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas A, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network Meta-analysis. Ann Intern Med. 2020;173:278\u201386.","journal-title":"Ann Intern Med"},{"key":"1203_CR62","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-1-4939-2522-3_15","volume":"1292","author":"A Dandekar","year":"2015","unstructured":"Dandekar A, Mendez R, Zhang K. Cross talk between ER stress, oxidative stress, and inflammation in health and disease. Methods Mol Biol. 2015;1292:205\u201314.","journal-title":"Methods Mol Biol"},{"key":"1203_CR63","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.molmed.2012.06.010","volume":"18","author":"AD Garg","year":"2012","unstructured":"Garg AD, et al. ER stress-induced inflammation: does it aid or impede disease progression? Trends Mol Med. 2012;18:589\u201398.","journal-title":"Trends Mol Med"},{"key":"1203_CR64","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/jcp.25098","volume":"231","author":"SS Cao","year":"2016","unstructured":"Cao SS, Luo KL, Shi L. Endoplasmic reticulum stress interacts with inflammation in Human diseases. J Cell Physiol. 2016;231:288\u201394.","journal-title":"J Cell Physiol"},{"key":"1203_CR65","doi-asserted-by":"publisher","first-page":"12602","DOI":"10.1096\/fj.201901050R","volume":"33","author":"X Hou","year":"2019","unstructured":"Hou X, et al. CK19 stabilizes CFTR at the cell surface by limiting its endocytic pathway degradation. FASEB J. 2019;33:12602\u201315.","journal-title":"FASEB J"},{"key":"1203_CR66","doi-asserted-by":"publisher","first-page":"13001","DOI":"10.1128\/JVI.76.24.13001-13014.2002","volume":"76","author":"KJ Blight","year":"2002","unstructured":"Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002;76:13001\u201314.","journal-title":"J Virol"},{"key":"1203_CR67","doi-asserted-by":"crossref","unstructured":"Levardon H, Yonker LM, Hurley BP, Mou H. Expansion of Airway Basal Cells and generation of polarized epithelium. Bio Protoc 8, (2018).","DOI":"10.21769\/BioProtoc.2877"}],"container-title":["Cell &amp; Bioscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13578-024-01203-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13578-024-01203-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13578-024-01203-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T23:38:55Z","timestamp":1708645135000},"score":1,"resource":{"primary":{"URL":"https:\/\/cellandbioscience.biomedcentral.com\/articles\/10.1186\/s13578-024-01203-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1203"],"URL":"https:\/\/doi.org\/10.1186\/s13578-024-01203-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3112506\/v1","asserted-by":"object"}]},"ISSN":["2045-3701"],"issn-type":[{"value":"2045-3701","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"27 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}